Ambulatory oxygen in interstitial lung disease

Visca, Dina; Montgomery, Andrew J.; Lauretis, Angelo De; Sestini, Piersante; Soteriou, Helen; Maher, Toby M.; Wells, AU; Renzoni, Elisabetta A.

doi:10.1183/09031936.00190710

Cited by 105 publications

(92 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As complicações associadas com a FPI -como hospitalização por exacerbações agudas e infecções do trato respiratório -contribuem para um significativo uso de recursos de saúde, visto que os pacientes muitas vezes necessitam de um longo tempo de permanência hospitalar. Com o progredir da doença, na fase avançada, os pacientes necessitam de terapias onerosas, como, por exemplo, o uso constante de oxigênio, sendo que, em alguns casos, é necessário um grande fornecimento de cilindros de oxigênio que são enviados para as casas dos pacientes (Mooney et al, 2016;Visca et al, 2011).…”

Section: Conclusãounclassified

See 1 more Smart Citation

Análise de custo-efetividade de pirfenidona em comparação a nintedanibe no tratamento de fibrose pulmonar idiopática na perspectiva do sistema suplementar de saúde brasileiro

Ho¹,

Ltd.²,

Rufino³

et al. 2017

JBES

View full text Add to dashboard Cite

Section: Conclusãounclassified

“…Em termos econômicos, a FPI, mesmo sendo uma doença rara, tem elevado impacto econômico (Mooney et al, 2016;Visca et al, 2011).…”

Section: Introductionunclassified

Análise de custo-efetividade de pirfenidona em comparação a nintedanibe no tratamento de fibrose pulmonar idiopática na perspectiva do sistema suplementar de saúde brasileiro

Ho¹,

Ltd.²,

Rufino³

et al. 2017

JBES

View full text Add to dashboard Cite

“…114,115 One retrospective study reported improved exertional capabilities, oxygen saturations, and dyspnea scores among 52 patients with interstitial lung disease, but quality of life was not assessed. 116 In contrast to COPD, impaired gas exchange and circulatory limits represent the major impediments during exercise in patients with interstitial lung disease, in contrast to abnormal ventilatory mechanics experience with COPD. 117,118 LTOT may have different ef-fects and different indications for use in these different pathophysiologic settings.…”

Section: Oxygen For Chronic Lung Diseases Other Than Copdmentioning

confidence: 99%

The Story of Oxygen

Heffner

2012

Respir Care

View full text Add to dashboard Cite

The history of oxygen from discovery to clinical application for patients with chronic lung disease represents a long and storied journey. Within a relatively short period, early investigators not only discovered oxygen but also recognized its importance to life and its role in respiration. The application of oxygen to chronic lung disease, however, took several centuries. In the modern era, physiologists pursued the chemical nature of oxygen and its physiologic interaction with cellular metabolism and gas transport. It took brazen clinicians, however, to pursue oxygen as a therapeutic resource for patients with chronic lung disease because of the concern in the 20th century of the risks of oxygen toxicity. Application of ambulatory oxygen devices allowed landmark investigations of the long-term effects of continuous oxygen that established its safety and efficacy. Although now well established for hypoxic patients, many questions remain regarding the benefits of oxygen for varying severity and types of chronic lung disease.

show abstract

“…There are a handful of small studies which suggest use of supplemental oxygen in IPF may improve both exercise capacity and breathlessness (43)(44)(45). The outcome of a RCT investigating the usefulness of oxygen in fibrotic lung disease will hopefully help generate guidelines on the use of ambulatory oxygen in IPF (46).…”

Section: Ambulatory Oxygen Therapymentioning

confidence: 99%

Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age

Shaw¹,

Marshall²,

Morris³

et al. 2017

J. Thorac. Dis.

View full text Add to dashboard Cite

Idiopathic pulmonary fibrosis (IPF) is the most common cause of interstitial lung disease (ILD) and carries a worse prognosis than many cancers. Until recently, there were no active treatment options available for patients with IPF, meaning palliation or lung transplantation in selected patients were the only options. The management of IPF has changed dramatically over the last decade with the advent of two antifibrotic agents; pirfenidone and nintedanib. These new agents have been shown to reduce decline in lung function and pirfenidone has been shown to reduce mortality. The changing landscape of IPF diagnosis and management present a number of issues that may be encountered including management of side effects related to antifibrotic therapy. This article aims to give an overview of the holistic approach to the management of patients with IPF, including antifibrotic management, symptom management and the invaluable role of the ILD specialist nurse.

show abstract

Ambulatory oxygen in interstitial lung disease

Cited by 105 publications

References 8 publications

Análise de custo-efetividade de pirfenidona em comparação a nintedanibe no tratamento de fibrose pulmonar idiopática na perspectiva do sistema suplementar de saúde brasileiro

Análise de custo-efetividade de pirfenidona em comparação a nintedanibe no tratamento de fibrose pulmonar idiopática na perspectiva do sistema suplementar de saúde brasileiro

The Story of Oxygen

Idiopathic pulmonary fibrosis: a holistic approach to disease management in the antifibrotic age

Contact Info

Product

Resources

About